Beyond their established role in T2D, GLP-1RAs are under investigation for potential therapeutic applications in additional clinical domains: non-alcoholic fatty liver disease (NAFLD) [22], neurodegenerative conditions [23], and addiction reduction(including smoking, alcohol use disorder, and cocaine use disorder, putatively via mechanisms analogous to those underlying appetite suppression) [23]
We prefer a BMI under 30 for the safest results, but we evaluate every patient individually
Medical Director for UK & USMedExpress In this interview, News Medical speaks with Dr Bryony Henderson , Medical Director for the UK and US at MedExpress , about the evolving role of GLP1 agonists in obesity care and the future of metabolic health treatments
A properly dosed GLP-1 might bring these down to 115 mg/dL (6.4 mmol/L) pre-meal and 160 mg/dL (8.9 mmol/L) after meals within 8-12 weeks
Built for GLP-1 so you always know where you stand and what to do next
A similar result was achieved also for CPT1B, CPT1C, and CAT (Kim et al., 2016)